MARKET

NURO

NURO

NeuroMetrix
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.720
+0.180
+11.69%
Closed 19:20 09/25 EDT
OPEN
1.520
PREV CLOSE
1.540
HIGH
1.800
LOW
1.500
VOLUME
452.98K
TURNOVER
--
52 WEEK HIGH
6.20
52 WEEK LOW
0.8120
MARKET CAP
6.51M
P/E (TTM)
-0.5274
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
GME, CVNA among premarket gainers
AIM ImmunoTech (AIM) +25% on receiving significant positive survival results in pancreatic cancer from Erasmus University Medical Center.GameStop (GME) +18% after RC Ventures discloses stake.Rockwell Medical (RMTI) +13%.Cassava Sciences (SAVA) +13% on insider buying.Carvana (CVNA) +13% as
Seekingalpha · 5d ago
NeuroMetrix Launches Quell Pain Relief Device App For Apple Watch
WOBURN, Mass., Sept. 22, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc.(NASDAQ:NURO) today reported the launch of the Quell Watch App, now available for download from the Apple App store.   Quell is a wearable,
Benzinga · 5d ago
NeuroMetrix Launches Quell® App for Apple Watch®, the First Smartwatch App for an Over-the-Counter Pain Relief Device
Quell® Watch App The Quell Watch app gives a Quell user the ability to control and monitor their pain relief from their Apple Watch®WOBURN, Mass., Sept. 22, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported the launch of the Quell Watch App, now available for download from the
GlobeNewswire · 5d ago
NeuroMetrix patents Quell wearable technology
NeuroMetrix (NURO) patents 'Apparatus and Method for Relieving Pain Using Transcutaneous Electrical Nerve Stimulation.'The patent covers core Quell technology that regulates electrical stimulation based on the device orientation.“We are continually working to
Seekingalpha · 6d ago
NeuroMetrix Announces Issuance of New U.S. Patent for Quell® Wearable Technology
WOBURN, Mass., Sept. 21, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that the U.S. Patent and Trademark Office will issue on September 22, 2020 U.S. Patent No. 10,780,269 titled “Apparatus and Method for Relieving Pain Using Transcutaneous Electrical Nerve Stimulation."
GlobeNewswire · 6d ago
NeuroMetrix Reports Scientific Presentation at the PAINWeek 2020 Live Virtual Conference
WOBURN, Mass., Sept. 04, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported that it will present a scientific poster at the PAINWeek 2020 Live Virtual Conference to be held September 11 - 13.  PAINWeek is the preferred resource in the U.S. for frontline practitioners treating acute
GlobeNewswire · 09/04 11:00
NeuroMetrix Reports Publication of Study Validating DPNCheck® Staging of Diabetic Peripheral Neuropathy Severity
WOBURN, Mass., Sept. 01, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported the publication of a large study demonstrating that DPNCheck effectively determines the severity of diabetic peripheral neuropathy (DPN).  DPNCheck is a widely used point-of-care test that provides fast,
GlobeNewswire · 09/01 17:00
NeuroMetrix Granted Canadian Patent Titled 'APPARATUS AND METHOD FOR THE AUTOMATED MEASUREMENT OF SURAL NERVE CONDUCTION VELOCITY AND AMPLITUDE'
https://www.ic.gc.ca/opic-cipo/cpd/eng/patent/2811330/summary.html
Benzinga · 08/25 14:20
More
Forecast
EPSBVPSCFPS
Actual (K USD)
Estimate (K USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NURO. Analyze the recent business situations of NeuroMetrix through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NURO stock price target is 50.00 with a high estimate of 50.00 and a low estimate of 50.00.
EPS
Institutional Holdings
Institutions: 19
Institutional Holdings: 1.79M
% Owned: 47.40%
Shares Outstanding: 3.78M
TypeInstitutionsShares
Increased
4
744.93K
New
4
43.47K
Decreased
1
6.83K
Sold Out
2
29.14K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
+2.16%
Healthcare Equipment & Supplies
+2.01%
Key Executives
Chairman/Chief Executive Officer/President/Secretary/Director
Shai Gozani
Chief Financial Officer/Senior Vice President/Treasurer
Thomas Higgins
Senior Vice President
Francis McGillin
Independent Director
David Goodman
Independent Director
Nancy Katz
Independent Director
David Van Avermaete
  • Dividends
  • Splits
  • Insider Activity
Declaration Date
Dividend Per Share
Ex-Div Date
03/14/2007
Dividend USD 0.15
03/28/2007
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About NURO
NeuroMetrix, Inc. is a healthcare company combining bioelectrical and digital medicine to address chronic health conditions, including chronic pain, sleep disorders and diabetes. The Company is engaged in the sale of medical equipment, and consumables and accessories. It has two principal product lines: Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests. Its products include ADVANCE NCS/EMG System (the ADVANCE System), Quell, SENSUS and DPNCheck. Quell is a wearable device for relief of chronic intractable pain, such as nerve pain due to diabetes and lower back problems. The SENSUS pain therapy device, the technological predecessor to Quell, is a prescription neuro-stimulation device based on transcutaneous electrical nerve stimulation (TENS) for relief of chronic, intractable pain. DPNCheck is a quantitative nerve conduction test. ADVANCE System is a platform for the performance of traditional nerve conduction studies.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Neurometrix Inc stock information, including NASDAQ:NURO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NURO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NURO stock methods without spending real money on the virtual paper trading platform.